PMID- 27416091
OWN - NLM
STAT- MEDLINE
DCOM- 20170418
LR  - 20170418
IS  - 2326-6929 (Electronic)
IS  - 0011-4162 (Linking)
VI  - 97
IP  - 6
DP  - 2016 Jun
TI  - Skin lesions in patients treated with imatinib mesylate: a 5-year prospective 
      study.
PG  - E12-6
AB  - Imatinib mesylate (IM) represents the first-line treatment of patients with 
      chronic myeloid leukemia (CLM) or gastrointestinal stromal tumor (GIST). It 
      presents several side effects. However, less than 10% are nonhematologic 
      including nausea, vomiting, diarrhea, muscle cramps, and cutaneous reactions. The 
      aim of our study was to identify data regarding IM cutaneous adverse effects 
      (AEs) to improve the clinical diagnosis and management of the more frequent side 
      effects. Skin examination should be done before and during IM treatment so that 
      AEs can be diagnosed and treated early with less impact on chemotherapy 
      treatments and on the quality of life of the patient.
FAU - Paolino, Giovanni
AU  - Paolino G
AD  - Dermatology Clinic, Department of Internal Medicine and Medical Specialties, 
      University of Rome, Italy.
FAU - Didona, Dario
AU  - Didona D
AD  - Dermatology Clinic, Department of Internal Medicine and Medical Specialties, 
      University of Rome, Italy.
FAU - Clerico, Rita
AU  - Clerico R
AD  - Dermatology Clinic, Department of Internal Medicine and Medical Specialties, 
      University of Rome, Italy.
FAU - Corsetti, Paola
AU  - Corsetti P
AD  - Dermatology Clinic, Department of Internal Medicine and Medical Specialties, 
      University of Rome, Italy.
FAU - Ambrifi, Marina
AU  - Ambrifi M
AD  - Dermatology Clinic, Department of Internal Medicine and Medical Specialties, 
      University of Rome, Italy.
FAU - Bottoni, Ugo
AU  - Bottoni U
AD  - Dermatology Clinic, Department of Internal Medicine and Medical Specialties, 
      University of Rome, Italy; University Magna Graecia, Catanzaro, Italy.
FAU - Calvieri, Stefano
AU  - Calvieri S
AD  - Dermatology Clinic, Department of Internal Medicine and Medical Specialties, 
      University of Rome, Italy.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Antineoplastic Agents)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects
MH  - Carcinoma, Basal Cell/chemically induced
MH  - Dermatitis, Seborrheic/chemically induced
MH  - Dermatomycoses/chemically induced
MH  - Drug Eruptions/*etiology
MH  - Eczema/chemically induced
MH  - Edema/chemically induced
MH  - Female
MH  - Gastrointestinal Neoplasms/*drug therapy
MH  - Gastrointestinal Stromal Tumors/*drug therapy
MH  - Histiocytoma, Benign Fibrous/chemically induced
MH  - Humans
MH  - Imatinib Mesylate/*adverse effects
MH  - Keratosis, Actinic/chemically induced
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Nail Diseases/chemically induced
MH  - Orbital Diseases/chemically induced
MH  - Prospective Studies
MH  - Pruritus/chemically induced
MH  - Psoriasis/chemically induced
MH  - Skin Neoplasms/chemically induced
EDAT- 2016/07/16 06:00
MHDA- 2017/04/19 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/16 06:00 [pubmed]
PHST- 2017/04/19 06:00 [medline]
PST - ppublish
SO  - Cutis. 2016 Jun;97(6):E12-6.